Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 40Active not recruiting 17Not yet recruiting 14Completed 3Suspended 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Eyelid Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 25Magnetic Resonance Spectroscopy 17Biopsy 15Cyclophosphamide 6venetoclax 5Vincristine 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3X-Rays 3Taxes 3Radiation 3Injections 3Cetuximab 3trastuzumab deruxtecan 2fludarabine 2decitabine and cedazuridine drug combination 2cemiplimab 2Tacrolimus 2Standard of Care 2Sirolimus 2Radiotherapy 2Radiosurgery 2Prednisone 2Practice Guidelines as Topic 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × cemiplimab × 90 days × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Duke University

Phase 2 Suspended
126 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡